Pressmeddelande

BioStock: Curasight announces brain cancer as initial target for uTREAT

Cision Publicerad: 15 Nov 08:45

Brain cancer will be the first indication for Curasight’s uTREAT therapy. The company’s decision to choose aggressive brain cancer for a fast single indications trial is backed by promising preclinical and clinical results demonstrating the potential of its uPAR-targeted technologies in neuro-oncology. Curasight aims to begin dosing the first patient in a clinical trial by the end of the second quarter of 2025. BioStock contacted CEO Ulrich Krasilnikoff to learn more.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/11/curasight-announces-brain-cancer-as-initial-target-for-utreat/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Nyheter om Curasight

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!